Sana Biotechnology Announces 5 Presentations at the 65th
4 min readSEATTLE, Nov. 02, 2023 (World NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a enterprise targeted on altering the possible for patients via engineered cells, right now announced that 5 abstracts will have poster displays at the 65th American Modern society of Hematology Once-a-year Meeting to be held December 9-12, 2023 in San Diego, CA.
| Facts of the poster displays are as follows: | |
| Title: | Hypoimmune, Allogeneic CD22-Directed Vehicle T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment method of Big B Cell Lymphoma Individuals That Are Relapsed/Refractory to CD19-Directed CAR T Mobile Remedy |
| Abstract Amount: | 3437 |
| Session Identify: | 703. Mobile Immunotherapies: Primary and Translational: Poster II |
| Session Day: | Sunday, December 10, 2023 |
| Presentation Time: | 6:00 PM – 8:00 PM |
| Spot: | San Diego Convention Centre, Halls G-H |
| Title: | Efficient and Precise In Vivo Genetic Engineering of Human Hematopoietic Stem Progenitor Cells devoid of Selective Conditioning |
| Abstract Variety: | 2252 |
| Session Identify: | 801. Gene Therapies: Poster I |
| Session Date: | Saturday, December 9, 2023 |
| Presentation Time: | 5:30 PM – 7:30 PM |
| Place: | San Diego Conference Heart, Halls G-H |
| Title: | Progress of a Novel, Allogeneic GPRC5D-Directed Car or truck for Treatment of A number of Myeloma Individuals |
| Summary Range: | 3290 |
| Session Title: | 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II |
| Session Day: | Sunday, December 10, 2023 |
| Presentation Time: | 6:00 PM – 8:00 PM |
| Site: | San Diego Conference Heart, Halls G-H |
| Title: | In Vitro and In Vivo Specificity and Biodistribution of a Novel CD8-Targeted Fusosome |
| Abstract Quantity: | 3630 |
| Session Title: | 801. Gene Therapies: Poster II |
| Session Date: | Sunday, December 10, 2023 |
| Presentation Time: | 6:00 PM – 8:00 PM |
| Spot: | San Diego Convention Centre, Halls G-H |
| Title: | Feasibility of Extracorporeal Delivery of Fusosomes to Produce Vehicle T Cells In Vivo |
| Summary Quantity: | 3631 |
| Session Identify: | 801. Gene Therapies: Poster II |
| Session Date: | Sunday, December 10, 2023 |
| Presentation Time: | 6:00 PM – 8:00 PM |
| Area: | San Diego Conference Middle, Halls G-H |
Whole abstracts are readily available for on the net viewing by using the ASH Once-a-year Assembly site at Hematology.org.
About Sana Biotechnology
Sana Biotechnology, Inc. is concentrated on creating and providing engineered cells as medicines for clients. We share a eyesight of controlling genes, replacing missing or destroyed cells, and making our therapies broadly accessible to people. We are a passionate team of men and women functioning with each other to make an enduring enterprise that variations how the entire world treats condition. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more details about Sana Biotechnology, you should stop by https://sana.com/.
Cautionary Observe With regards to Forward-Wanting Statements
This press launch is made up of forward-wanting statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the that means of the federal securities laws, which includes those people linked to the Company’s eyesight expectations for the Company’s participation at the 65th American Society of Hematology Yearly Meeting and expectations for the Company’s displays at this sort of assembly, which include the information of these types of shows. All statements other than statements of historical information contained in this push launch, including, between other individuals, statements relating to the Company’s technique, anticipations, hard cash runway and future monetary problem, upcoming operations, and prospective customers, are ahead-seeking statements. In some situations, you can identify forward-searching statements by terminology these as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other very similar expressions that are predictions of or reveal long run occasions and potential trends, or the negative of these phrases or other similar terminology. The Company has centered these forward-hunting statements mainly on its recent expectations, estimates, forecasts and projections about foreseeable future functions and fiscal developments that it thinks may perhaps impact its economic situation, benefits of operations, company technique and fiscal requires. In light-weight of the sizeable uncertainties in these forward-looking statements, you must not depend on forward-on the lookout statements as predictions of long term occasions. These statements are topic to pitfalls and uncertainties that could result in the precise effects to range materially, which includes, among other people, the hazards inherent in drug progress these types of as all those connected with the initiation, price, timing, progress and outcomes of the Company’s recent and long run analysis and enhancement applications, preclinical and clinical trials, as very well as financial, market and social disruptions. For a comprehensive discussion of the danger things that could affect the Company’s true success, please refer to the chance components discovered in the Company’s SEC experiences, including but not limited to its Quarterly Report on Variety 10-Q dated August 3, 2023. Apart from as required by regulation, the Enterprise undertakes no obligation to update publicly any forward-hunting statements for any reason.
Investor Relations & Media:
Nicole Keith
[email protected]
[email protected]
